Sign in

601607 on Shanghai Stock Exchange

Shanghai Pharmaceuticals

Chinese pharmaceutical company

Shanghai Pharmaceuticals (Chinese: 上海医药, also referred as Shanghai Pharma) is a private-sector Chinese pharmaceutical company. The organization develops and distributes pharmaceutical products and operates in domestic and international markets. Shanghai Pharma is the largest pharmaceutical and the first A+H listed company in China to be dual-listed by Shanghai and Hong Kong Stock Exchanges.2 Its revenue was CN¥159 billion in 2018.1 Its shares trade on Shanghai Stock Exchange under the symbol 601607.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

Oct 1952Founded1

Compare with another stock.

  • Ticker601607 on Shanghai Stock Exchange1
  • Websitewww.pharm-sh.com.cn
  • Listed onHong Kong Stock Exchange, Shanghai Stock Exchange (601607)1

See how the biggest companies compare on our leaderboards

Shanghai Pharmaceuticals (Chinese: 上海医药, also referred as Shanghai Pharma) is a private-sector Chinese pharmaceutical company. The organization develops and distributes pharmaceutical products and operates in domestic and international markets.2

Corporate structure

Shanghai Pharmaceuticals sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Subsidiaries and ownership

Subsidiaries

From Wikidata.1

Revenue over time

As stated on Wikidata, in the currency reported.

Revenue

  • 2018159.1B CNY1

Timeline

  1. Oct 1952Founded Founded1

Calendar

Drug trials and FDA: coming up

  1. Dec 1, 2026Phase 2/3 trial readout expected Phase 2/3 trial of SPH4336 Tablets in Locally Advanced or Metastatic Breast Cancer: primary completion expected Dec 1, 2026 (ClinicalTrials.gov NCT05860465).3
  2. Dec 10, 2026Phase 2 trial readout expected Phase 2 trial of LT3001 Drug:high dose and LT3001 Drug:low dose in Acute Ischemic Stroke: primary completion expected Dec 10, 2026 (ClinicalTrials.gov NCT05686642).4
  3. Dec 30, 2026Phase 2/3 trial readout expected Phase 2/3 trial of B007 in Generalized Myasthenia Gravis, run by Shanghai Jiaolian Drug Research and Development Co., Ltd: primary completion expected Dec 30, 2026 (ClinicalTrials.gov NCT06447597).5
  4. Dec 31, 2026Phase 2/3 trial readout expected Phase 2/3 trial of B007 in Pemphigus, run by Shanghai Jiaolian Drug Research and Development Co., Ltd: primary completion expected Dec 31, 2026 (ClinicalTrials.gov NCT06454357).6
  5. Dec 31, 2026Phase 2/3 trial readout expected Phase 2/3 trial of B007 and Cyclosporin Capsules in Primary Membranous Nephropathy, run by Shanghai Jiaolian Drug Research and Development Co., Ltd: primary completion expected Dec 31, 2026 (ClinicalTrials.gov NCT06470191).7
  6. Dec 31, 2026Phase 2 trial readout expected Phase 2 trial of SPH4336 Tablets in Breast Cancer Brain Metastases: primary completion expected Dec 31, 2026 (ClinicalTrials.gov NCT05872347).8

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8